{"result": "(\"entity\"<|>HÍGADO<|>GEO<|>The liver is an organ that may require transplantation in severe cases of glycogenosis that do not respond well to nutritional treatment.)\n##\n(\"entity\"<|>RIÑÓN<|>GEO<|>The kidney is an organ that may require transplantation in patients with glycogenosis type Ia and terminal renal insufficiency.)\n##\n(\"entity\"<|>CIRROSIS<|>EVENT<|>Cirrhosis is a potential complication of glycogenosis that may occur if the condition is not managed properly.)\n##\n(\"entity\"<|>HEPATOCARCINOMA<|>EVENT<|>Hepatocarcinoma is a type of liver cancer that may develop in patients with glycogenosis type I who have multiple adenomas or are at risk.)\n##\n(\"entity\"<|>NUTRICIÓN ENTERAL<|>EVENT<|>Enteral nutrition is a method of providing nutrition to patients with glycogenosis through a nasogastric tube, especially in severe cases.)\n##\n(\"relationship\"<|>HÍGADO<|>GLYCOGENOSIS<|>The liver may require transplantation in severe cases of glycogenosis that do not respond to treatment<|>7)\n##\n(\"relationship\"<|>RIÑÓN<|>GLYCOGENOSIS<|>The kidney may require transplantation in patients with glycogenosis type Ia and terminal renal insufficiency<|>7)\n##\n(\"relationship\"<|>CIRROSIS<|>GLYCOGENOSIS<|>Cirrhosis can develop as a complication in patients with glycogenosis if not managed properly<|>6)\n##\n(\"relationship\"<|>HEPATOCARCINOMA<|>GLYCOGENOSIS<|>Hepatocarcinoma is a risk for patients with glycogenosis type I who have multiple adenomas<|>6)\n##\n(\"relationship\"<|>NUTRICIÓN ENTERAL<|>GLYCOGENOSIS<|>Enteral nutrition is a critical treatment method for managing severe glycogenosis<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ratos de carbono, 30% por                     6.5.    Otros tratamientos\n       lípidos y 15% por proteínas. Es muy importante\n       seguir una ingesta metódica y frecuente, serían                         El calcio y la vitamina D a dosis individualizadas se-\n       unas 5 o 6 comidas al día, y cada 2 o 3 horas, el                    rían suplementos vitamínicos y minerales útiles en el\n       paciente debe tomar alimentos ricos en almidón.                      tratamiento de pacientes con glucogenosis hepáti-\n       Se debe evitar todo alimento que contenga lacto-                     cas30 . Se aconseja tratamiento con IECA si hay micro-\n       sa, sacarosa o fructosa (lácteos, frutas, azúcar),                   albuminuria y fibratos y/o inhibidores de la hidroxime-\n       por transformarse en lactato muy rápido y no                         tilglutaril coenzima A reductasa (estatinas) para la\n       conseguir la alimentación constante y en los nive-                   dislipemia.\n       les que se precisa de glucosa.                                          El trasplante hepático está indicado en algunas for-\n   b. Nutrición enteral nocturna por sonda nasogástri-                      mas graves que no responden bien al tratamiento nu-\n       ca. En los lactantes o niños sanos la velocidad de                   tricional y tienden a derivar a una cirrosis, así como en\n       producción de glucosa es de 5 a 8 mg por kilogra-                    el caso de que el paciente tuviese adenomas múltiples\n       mo de peso cada minuto; por ello, los que pade-                      o riesgo de hepatocarcinoma (I, III o IV)30, 34.\n       cen glucogenosis tipo I deben igualar o superar                         El trasplante renal en pacientes con subtipo Ia e insu-\n       esta cifra a una velocidad de 8 a 9 mg por kilogra-                  ficiencia renal terminal normaliza la función del riñón,\n       mo de peso por minuto; es distinto según el pa-                      pero no corrige la metabolopatía, por lo que puede\n       ciente y debe controlarse cada 3 o 6 meses, de-                      estar indicado un trasplante combinado de hígado y\n       biendo ser cuidadosos y evitando el exceso de                        riñón; en pacientes Ib el trasplante hepático corrige las\n       aporte, ya que podrían desarrollar anorexia diur-                    alteraciones metabólicas, pero no la neutropenia34, 35.\n       na, con incapacidad de tener un consumo apro-                           En la glucogenosis Ib específicamente se busca pre-\n       piado de hidratos de carbono y/o con una ingesta                     venir las infecciones y sus recidivas, y para ello se tratan\n       inadecuada de proteínas. Hay que evitar que se                       con factor recombinante humano estimulante de la\n       detenga bruscamente la perfusión de la nutrición                     colonia de granulocitos macrófagos (GM-CSF) a dosis\n       enteral y, si así fuese, deben ingerirse hidratos de                 de 7 mg/kg/día y factor estimulante de la colonia de\n       carbono media hora después de que finalice la                        granulocitos (G-CSF) a dosis de 3 mg/kg/día por vía\n       nutrición enteral.                                                   subcutánea.\n   c.  Almidón de maíz. Introducido en la dieta paulati-                       Algunos expertos defienden la profilaxis con antibió-\n       namente a lo largo del segundo año de vida o final                   ticos (normalmente cotrimoxazol). La vitamina E puede\n       del primer año, ha demostrado eficacia en la glu-                    mejorar las aftas.\n       cogenosis tipo I, aunque esta es variable. Se usará                     Las terapias dietéticas y el factor estimulante de colo-\n       una dilución a temperatura ambiente de Maizena                       nias combinados alivian de forma significativa las altera-\n       o almidón de maíz no cocido (siglas en inglés                        ciones metabólicas y mieloides de pacientes Ib y mejo-\n       UCCS, UnCooked Corn Starch) en niños más mayo-                       ran su pronóstico. Pero, cabe señalar que tras la terapia\n---\n 320      BLOQUE: PROTEÍNAS Y AMINOÁCIDOS\n\n\n\ncon factor estimulante de colonias un número conside-                     5.  Maillot F, Lilburn M, Baudin J, Morley DW, Lee PJ.\nrable de adultos desarrolla esplenomegalia30, 34, 35, 39.                     Factors influencing outcomes in the offspring of\n                                                                              mothers with Phenylketonuria during pregnancy:\n7.   Resumen                                                                  the importance of variation in maternal blood\n   Los errores innatos del metabolismo de los amino-                          phenylalanine. Am J Clin Nutr 2008; 88:700-5\nácidos son un conjunto de enfermedades caracteriza-                       6.  Zur\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>GLYCOGENOSIS<|>EVENT<|>Glycogenosis is a metabolic disorder affecting the body's ability to process glycogen, leading to various health complications.)\n##\n(\"entity\"<|>MAIZENA<|>ORGANIZATION<|>Maizena is a brand of corn starch used in dietary treatments for metabolic disorders, particularly glycogenosis type I.)\n##\n(\"entity\"<|>GM-CSF<|>ORGANIZATION<|>GM-CSF, or Granulocyte-Macrophage Colony-Stimulating Factor, is a medication used to stimulate the production of white blood cells in patients with certain metabolic disorders.)\n##\n(\"entity\"<|>G-CSF<|>ORGANIZATION<|>G-CSF, or Granulocyte Colony-Stimulating Factor, is a medication used to increase white blood cell counts in patients with metabolic disorders.)\n##\n(\"entity\"<|>VITAMIN E<|>ORGANIZATION<|>Vitamin E is a nutrient that may improve oral health issues in patients with metabolic disorders.)\n##\n(\"entity\"<|>COTRIMOXAZOL<|>ORGANIZATION<|>Cotrimoxazole is an antibiotic that may be used for prophylaxis in patients with metabolic disorders to prevent infections.)\n##\n(\"relationship\"<|>MAIZENA<|>GLYCOGENOSIS<|>Maizena is used in the dietary management of glycogenosis type I to help regulate glucose levels<|>7)\n##\n(\"relationship\"<|>GM-CSF<|>GLYCOGENOSIS<|>GM-CSF is administered to patients with glycogenosis to stimulate white blood cell production<|>8)\n##\n(\"relationship\"<|>G-CSF<|>GLYCOGENOSIS<|>G-CSF is used in the treatment of patients with glycogenosis to enhance white blood cell counts<|>8)\n##\n(\"relationship\"<|>VITAMIN E<|>GLYCOGENOSIS<|>Vitamin E may help alleviate oral health issues in patients suffering from glycogenosis<|>6)\n##\n(\"relationship\"<|>COTRIMOXAZOL<|>GLYCOGENOSIS<|>Cotrimoxazole is recommended for prophylaxis against infections in patients with glycogenosis<|>5)\n<|COMPLETE|>"}]}